CD274 and Merkel cell skin cancer: According to National Comprehensive Cancer Network guidelines, the current immunotherapy treatment paradigm for MCC involves the use of immune checkpoint inhibitors targeting PD-1 (e.g., pembrolizumab, nivolumab) and PD-L1 (e.g., avelumab) for distant metastatic disease [110].